Recent Quotes (30 days)

You have no recent quotes
chg | %

Ionis Pharmaceuticals Inc  

(Public, NASDAQ:IONS)   Watch this stock  
Find more results for NASDAQ:ISIS
-1.59 (-2.47%)
After Hours: 62.70 -0.10 (-0.16%)
Oct 23, 4:46PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 62.54 - 64.90
52 week 24.58 - 65.51
Open 64.43
Vol / Avg. 1.26M/1.35M
Mkt cap 7.81B
P/E 298.91
Div/yield     -
EPS 0.21
Shares 124.35M
Beta 3.12
Inst. own 92%
Nov 7, 2017
Q3 2017 Ionis Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 15, 2017
RARE Partnering and Investor Forum
Sep 13, 2017
Ionis Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 6, 2017
Ionis Pharmaceuticals Inc at Wells Fargo Healthcare Conference - Webcast
Aug 24, 2017
Ionis Pharmaceuticals Inc at Seaport Global Securities Southern California Investor Conference - Webcast
Aug 11, 2017
Ionis Pharmaceuticals Inc Conference Call to Discuss its Plan to Independently Advance Inotersen and IONIS-FB-L Rx - Webcast
Aug 8, 2017
Q2 2017 Ionis Pharmaceuticals Inc Earnings Call - Webcast
Aug 8, 2017
Q2 2017 Ionis Pharmaceuticals Inc Earnings Release
Aug 3, 2017
Ionis Pharmaceuticals Inc at Wells Fargo San Francisco Biotech Corporate Access Day
Aug 1, 2017
Ionis Pharmaceuticals Inc at Wells Fargo Boston Biotech Corporate Access Day
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -10.76% -24.97%
Operating margin -1.60% -14.51%
EBITD margin - -10.76%
Return on average assets -4.13% -9.31%
Return on average equity -21.54% -57.64%
Employees 435 -
CDP Score - -


2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Officers and directors

Stanley T. Crooke M.D. Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 72
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 63
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
Age: 43
Bio & Compensation  - Reuters
C. Frank Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 60
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 59
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 55
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 45
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Breaux B. Castleman Independent Director
Age: 76
Bio & Compensation  - Reuters